LAKE MARY, Fla. — Axium Healthcare Pharmacy announced that it will begin to dispense Otezla, the new oral therapy for the treatment of adults with active psoriatic arthritis. Axium is one of a limited number of specialty pharmacies selected by drug manufacturer Celgene to dispense Otezla, which was approved by the Food and Drug Administration on March 21.
PsA is an inflammatory type of arthritis that occurs in 10% to 30% of people with psoriasis. It occurs when the immune system attacks the joints and causes inflammation. In clinical trials, PsA patients treated with Otezla showed improvements in the signs and symptoms of PsA including tender and swollen joints, as well as physical function.
As a specialty pharmacy, Axium, along with medications like Otezla, is paving the way for better outcomes for patients with psoriatic arthritis, the company stated. Axium’s clinical expertise in psoriatic arthritis, combined with its ‘helping hand’ therapy management programs, helps to ensure that patients can maximize the benefits of their Otezla treatment.